FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045400538> ?p ?o ?g. }

• W2045400538 endingPage "c65" @default.
• W2045400538 startingPage "c58" @default.
• W2045400538 abstract "<i>Background:</i> End-stage renal disease (ESRD) patients are thought to have impaired 1-α-hydroxylase capacity, but an extrarenal source of 1,25(OH)₂D has been recognized. <i>Objective:</i> The aim of this study was to assess the evolution of serum 1,25(OH)₂D in hemodialysis (HD) patients with vitamin D deficiency after 6 months of 25(OH)D₃ supplementation, and to identify the factors associated with persistent 1,25(OH)₂D production. <i>Methods:</i> HD patients in a HD center with vitamin D deficiency (i.e. 25(OH)D <75 nmol/l) who were not receiving any vitamin D derivatives or calcimimetics were studied. Patients who had previously undergone parathyroidectomy or nephrectomy or those with uncontrolled hypercalcemia or hyperphosphatemia were excluded from this study. The patients were administrated a dose of 10–30 µg/day of oral 25(OH)D₃ based on the severity of their deficiency. The serum levels of 25(OH)D and 1,25(OH)₂D evolution after 6 months were recorded. Responders were defined as patients with an increase in serum 1,25(OH)₂D levels greater than the median value. Changes in mineral metabolism parameters were compared with those in the nonresponders. <i>Results:</i> Of the 253 patients, 225 (89%) were vitamin D-deficient, and 43 met the inclusion criteria. The patients were 72.6 ± 10 years old and had been on dialysis for 71 ± 70 months; 39% of the patients were female and 45% were diabetics. From baseline to 6 months of treatment, serum 25(OH)D levels increased from 27.8 ± 18 to 118 ± 34 nmol/l (p < 0.001) and serum 1,25(OH)₂D levels increased from 7.7 ± 5 to 30.5 ± 15 pmol/l (p < 0.001) with a median increase of 20 pmol/l. The mean serum calcium level increased from 2.19 ± 0.1 to 2.25 ± 0.1 mmol/l (p = 0.009), the intact parathyroid hormone (iPTH) level decreased from 144 ± 108 to 108 ± 63 pg/ml (p = 0.05), and the bone alkaline phosphatase (BALP) level remained unchanged. The serum phosphate level increased slightly from 1.22 ± 0.3 to 1.34 ± 0.2 mmol/l (p = 0.04) with reduced hypophosphatemia. Compared with the responders (n = 24), most of the nonresponders (n = 19) were diabetic (63 vs. 29%, p = 0.02) and had a lesser increase of their 25(OH)D serum level. The serum level of FGF-23 was not significant. A positive correlation was observed between serum 1,25(OH)₂D and serum 25(OH)D levels after 6 months of 25(OH)D₃ treatment (p = 0.02). <i>Conclusion:</i> The Kidney Disease Outcomes Quality Improvement (KDOQI) guidelines do not recommend checking and treating vitamin D deficiency in chronic kidney disease (CKD) stage 5 patients due to the supposed lack of 1,25(OH)₂D production. These data confirm persistent renal or extra-renal production of 1,25(OH)₂D in HD patients after 6 months of 25(OH)D₃ administration. Diabetes is the main factor associated with impaired 1,25(OH)₂D production. 25(OH)D₃administration corrects vitamin D deficiency with few effects on mineral metabolism and stability of bone turnover markers." @default.
• W2045400538 created "2016-06-24" @default.
• W2045400538 creator A5011758772 @default.
• W2045400538 creator A5014716606 @default.
• W2045400538 creator A5028617015 @default.
• W2045400538 creator A5032235532 @default.
• W2045400538 creator A5061597970 @default.
• W2045400538 creator A5063375019 @default.
• W2045400538 creator A5087764148 @default.
• W2045400538 date "2008-08-25" @default.
• W2045400538 modified "2023-09-23" @default.
• W2045400538 title "Evidence for Persistent Vitamin D 1-Alpha-Hydroxylation in Hemodialysis Patients: Evolution of Serum 1,25-Dihydroxycholecalciferol after 6 Months of 25-Hydroxycholecalciferol Treatment" @default.
• W2045400538 cites W131928399 @default.
• W2045400538 cites W1531471974 @default.
• W2045400538 cites W1849648692 @default.
• W2045400538 cites W1927171971 @default.
• W2045400538 cites W1967604492 @default.
• W2045400538 cites W1975446158 @default.
• W2045400538 cites W1990796758 @default.
• W2045400538 cites W1998092234 @default.
• W2045400538 cites W1999237472 @default.
• W2045400538 cites W2011382235 @default.
• W2045400538 cites W2014348675 @default.
• W2045400538 cites W2016008325 @default.
• W2045400538 cites W2017219647 @default.
• W2045400538 cites W2028302756 @default.
• W2045400538 cites W2031941775 @default.
• W2045400538 cites W2054905044 @default.
• W2045400538 cites W2057052202 @default.
• W2045400538 cites W2088644600 @default.
• W2045400538 cites W2105398326 @default.
• W2045400538 cites W2118932178 @default.
• W2045400538 cites W2119739932 @default.
• W2045400538 cites W2121814218 @default.
• W2045400538 cites W2124070987 @default.
• W2045400538 cites W2143311403 @default.
• W2045400538 cites W2145243501 @default.
• W2045400538 cites W2159185156 @default.
• W2045400538 cites W2165104274 @default.
• W2045400538 cites W2166745615 @default.
• W2045400538 cites W2184342921 @default.
• W2045400538 cites W2259182069 @default.
• W2045400538 cites W2325025334 @default.
• W2045400538 cites W2325704874 @default.
• W2045400538 cites W2336662282 @default.
• W2045400538 cites W2410101586 @default.
• W2045400538 cites W633735835 @default.
• W2045400538 cites W2063868004 @default.
• W2045400538 doi "https://doi.org/10.1159/000151534" @default.
• W2045400538 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18724068" @default.
• W2045400538 hasPublicationYear "2008" @default.
• W2045400538 type Work @default.
• W2045400538 sameAs 2045400538 @default.
• W2045400538 citedByCount "69" @default.
• W2045400538 countsByYear W20454005382012 @default.
• W2045400538 countsByYear W20454005382013 @default.
• W2045400538 countsByYear W20454005382014 @default.
• W2045400538 countsByYear W20454005382015 @default.
• W2045400538 countsByYear W20454005382016 @default.
• W2045400538 countsByYear W20454005382017 @default.
• W2045400538 countsByYear W20454005382018 @default.
• W2045400538 countsByYear W20454005382019 @default.
• W2045400538 countsByYear W20454005382021 @default.
• W2045400538 countsByYear W20454005382023 @default.
• W2045400538 crossrefType "journal-article" @default.
• W2045400538 hasAuthorship W2045400538A5011758772 @default.
• W2045400538 hasAuthorship W2045400538A5014716606 @default.
• W2045400538 hasAuthorship W2045400538A5028617015 @default.
• W2045400538 hasAuthorship W2045400538A5032235532 @default.
• W2045400538 hasAuthorship W2045400538A5061597970 @default.
• W2045400538 hasAuthorship W2045400538A5063375019 @default.
• W2045400538 hasAuthorship W2045400538A5087764148 @default.
• W2045400538 hasConcept C124490489 @default.
• W2045400538 hasConcept C126322002 @default.
• W2045400538 hasConcept C134018914 @default.
• W2045400538 hasConcept C2775945674 @default.
• W2045400538 hasConcept C2776036575 @default.
• W2045400538 hasConcept C2777645128 @default.
• W2045400538 hasConcept C2778063415 @default.
• W2045400538 hasConcept C2778653478 @default.
• W2045400538 hasConcept C2778838027 @default.
• W2045400538 hasConcept C2779740938 @default.
• W2045400538 hasConcept C2781208988 @default.
• W2045400538 hasConcept C519063684 @default.
• W2045400538 hasConcept C71924100 @default.
• W2045400538 hasConceptScore W2045400538C124490489 @default.
• W2045400538 hasConceptScore W2045400538C126322002 @default.
• W2045400538 hasConceptScore W2045400538C134018914 @default.
• W2045400538 hasConceptScore W2045400538C2775945674 @default.
• W2045400538 hasConceptScore W2045400538C2776036575 @default.
• W2045400538 hasConceptScore W2045400538C2777645128 @default.
• W2045400538 hasConceptScore W2045400538C2778063415 @default.
• W2045400538 hasConceptScore W2045400538C2778653478 @default.
• W2045400538 hasConceptScore W2045400538C2778838027 @default.
• W2045400538 hasConceptScore W2045400538C2779740938 @default.
• W2045400538 hasConceptScore W2045400538C2781208988 @default.
• W2045400538 hasConceptScore W2045400538C519063684 @default.
• W2045400538 hasConceptScore W2045400538C71924100 @default.

• next